Depo-Provera has been used by millions of women as a convenient and long-lasting contraceptive option. However, recent concerns have emerged about a possible link between the long-term use of these ...

At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...

The MarketWatch News Department was not involved in the creation of this content. The number of lawsuits filed has tripled to over 1300 since May New US peer-reviewed study adds to body of research ...

For decades, women have trusted Depo-Provera, a birth control injection manufactured by Pfizer, as a convenient and effective contraceptive option. However, recent research has uncovered alarming ...

A new study has found a link between progestogen medications and an increased risk of brain tumours. The study, which was published in the British Medical Journal (BMJ) by researchers at France’s ...

Depo Provera Brain Tumor: Medroxyprogesterone acetate, a contraceptive injection containing the hormone progestin, is widely known by its brand name, Depo-Provera. Administered every three months, it ...

Women who use Depo-Provera face a higher risk of developing a slow-growing brain tumor, according to a new study that comes as the contraceptive’s maker, Pfizer, faces hundreds of lawsuits claiming ...

"It could be big. I think it could be as big as some of the others we've gotten here," Anapol Weiss shareholder Kila Baldwin said. In March, neurosurgeons and researchers in France published a large ...

A woman who lost half her teeth due to the contraceptive jab wants to warn others about the dangers of staying on the period-stopping medication for 'too long'. Alexandra Hale, 32, was first ...

A new study has found a link between progestogen medications and an increased risk of brain tumours. The study, which was published in the British Medical Journal (BMJ) by researchers at France’s ...

PENSACOLA, Fla.--(BUSINESS WIRE)--At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which ...